FDA warns Merck over its promotion of rofecoxib.
Josefson
D
D
D000925:Anticoagulants / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D004345:Drug Industry; D004347:Drug Interactions; D004335:Drug and Narcotic Control; D007783:Lactones / Q000009:adverse effects* / Q000494:pharmacology; D020521:Stroke / Q000139:chemically induced; D013450:Sulfones; D014481:United States; D014486:United States Food and Drug Administration; D014859:Warfarin / Q000494:pharmacology
D000925:Anticoagulants; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D014859:Warfarin